|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Fixed maturity securities available-for-sale, at fair value (amortized cost of $116,308 and $107,264; allowance for credit losses of $246 and $210) | ||||||||||||||||||||
| Available-for-sale Securities, Equity Securities | ||||||||||||||||||||
| Mortgage loans (net of allowance for credit losses of $127 and $117) | ||||||||||||||||||||
| Policy loans | ||||||||||||||||||||
| Funds withheld at interest | ||||||||||||||||||||
| Real Estate Investments, Joint Ventures | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Other invested assets | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accrued investment income | ||||||||||||||||||||
| Premiums receivable and other reinsurance balances | ||||||||||||||||||||
| Reinsurance Recoverables, Including Reinsurance Premium Paid | ||||||||||||||||||||
| Deferred policy acquisition costs and other | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Market Risk Benefit, Net Amount at Risk | ||||||||||||||||||||
| Funds Held under Reinsurance Agreements, Liability | ||||||||||||||||||||
| Liabilities and equity | ||||||||||||||||||||
| Future policy benefits | ||||||||||||||||||||
| Interest-sensitive contract liabilities | ||||||||||||||||||||
| Other policy claims and benefits | ||||||||||||||||||||
| Other reinsurance balances | ||||||||||||||||||||
| Income taxes | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Equity | ||||||||||||||||||||
| Preferred stock (par value $0.01 per share, 10,000,000 shares authorized, no shares issued or outstanding) | ||||||||||||||||||||
| Common stock (par value $0.01 per share, 140,000,000 shares authorized, 85,310,598 shares issued at June 30, 2026 and December 31, 2025) | ||||||||||||||||||||
| Additional paid-in-capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Treasury stock, at cost (20,018,604 and 19,846,934 shares at June 30, 2026 and December 31, 2025) | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Total RGA, Inc. shareholders’ equity | ||||||||||||||||||||
| Stockholders' Equity Attributable to Noncontrolling Interest | ||||||||||||||||||||
| Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
Loading...
